The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy
Abstract
Distinguishing corticobasal degeneration (CBD) from progressive supranuclear palsy (PSP) is clinically and pathologically difficult, and a useful biological marker to discriminative these two diseases has been a subject of clinical interest. In the present study, we assessed tau protein levels in cerebrospinal fluids by sandwich ELISA to distinguish CBD from PSP. The subjects consisted of 27 cases of CBD, 30 cases of PSP, and 36 healthy controls (CTL). The tau values in CBD were significantly higher than those in PSP (P<0.001) and those in CTL (P<0.001). The assay of CSF tau provided diagnostic sensitivity of 81.5% and specificity of 80.0% between CBD and PSP according to receiver-operating characteristic (ROC) curve analysis. When values were compared separately with respect to stage of the disease, differences in the values for moderate CBD vs. moderate PSP had the greatest significance (P<0.001 sensitivity 92.3%, specificity 100.0%), followed by cases of mild CBD and PSP (P<0.005, sensitivity 100.0%, specificity 87.5%). The values in severe CBD and PSP were not significantly different (P=0.07, sensitivity 100%, specificity 75.0%). Using data obtained from a larger number of disease cases, we confirmed our previous findings that tau protein levels in cerebrospinal fluids in patients with CBD are significantly higher than those in patients with PSP. Because tau protein levels in cerebrospinal fluids are significantly higher in early CBD cases than in early PSP cases, measure…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Elevated CSF T-tau level is not specific to AD as it may also be elevated in other neurodegenerative diseases.
“However, clinical studies have shown that the elevated CSF T-tau level is not specific to AD as it may also be elevated in other neurodegenerative diseases (Arai et al., 1997; Urakami et al., 2001).”
From T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) · cites this paper as Urakami et al., 2001
Citations
Cites
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Flagged first, then by citations
Research works printed but not linked: 12
- Vandermeeren, 1993, Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay, J Neurochem, 61, 1828, 10.1111/j.1471-4159.1993.tb09823.x · DOI
- Arai, 1995, Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease, Ann Neurol, 38, 649, 10.1002/ana.410380414 · DOI
- Kanai, 1998, Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, Aβ1–42(43) in Alzheimer’s disease: A study in Japan, Ann Neurol, 44, 17, 10.1002/ana.410440108 · DOI · Paper page
- Mori, 1994, Corticobasal degeneration: a disease with wide-spread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy, Acta Neuropathol (Berl), 88, 113, 10.1007/BF00294503 · DOI
- Scully, 1993, Case records of the Massachusetts General Hospital, New Engl J Med, 329, 1560
- Urakami, 1999, A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy, Neurosci Lett, 259, 127, 10.1016/S0304-3940(98)00923-9 · DOI
- Rinne, 1994, Corticobasal degeneration a clinical study of 36 cases, Brain, 117, 1183, 10.1093/brain/117.5.1183 · DOI
- Morimatsu, 1995, Corticobasal degeneration: symptomatological brain-imaging and electrophysiological studies, Rinsho-Shinkeigaku [in Japanese], 35, 1459
- Mitani, 1998, Increased CSF tau protein in corticobasal degeneration, J Neurol, 245, 44, 10.1007/s004150050173 · DOI
- Arai, 1997, Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology, Biochem Biophys Res Comm, 236, 262, 10.1006/bbrc.1997.6908 · DOI · Paper page
- Ishiguro, 1999, Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease, Neurosci Lett, 270, 91, 10.1016/S0304-3940(99)00476-0 · DOI
- Otto, 1997, Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jacob disease, Neurosci Lett, 225, 210, 10.1016/S0304-3940(97)00215-2 · DOI
Cited by
Sorted by citations
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985
Progressive Supranuclear Palsy: Pathology and Genetics
Dickson, D. W., Rademakers, R., & Hutton, M. L. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00054.x · Cited by 314
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease
Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128
T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease
Haris, M., Yadav, S. K., Rizwan, A., Singh, A., Cai, K., Kaura, D., Wang, E., Davatzikos, C., Trojanowski, J. Q., Melhem, E. R., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.02.016 · Cited by 33
Metadata
- Authors
- Urakami, K., Wada, K., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ishizu, H., Kashihara, K., Yamamoto, M., Tsuchiya-Ikemoto, K., Morimatsu, M., Takashima, H., Nakagawa, M., Kurokawa, K., Maruyama, H., Kaseda, Y., Nakamura, S., Hasegawa, K., Oono, H., Hikasa, C., Ikeda, K., Yamagata, K., Wakutani, Y., Takeshima, T., & Nakashima, K.
- Affiliations
- Tottori University (JP)
- Tohoku University (JP)
- Gunma University (JP)
- Okayama University (JP)
- Kagawa Prefectural Central Hospital (JP)
- Yamaguchi University (JP)
- Kagoshima University (JP)
- Hiroshima University (JP)
- Kitasato University (JP)
- Corresponding author
- Urakami, K.
- ORCID
- Venue
- Journal of the Neurological Sciences
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 183
- Issue
- 1
- Pages
- 95-98
- ISSN
- 0022-510X (ISSN-L)
- OpenAlex
- W2084033054
- Cited by
- 97
- References
- 1
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 2 · 2022: 1 · 2021: 7 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 5 · 2012: 4
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein, cerebrospinal fluid biomarkers, corticobasal degeneration, progressive supranuclear palsy, differential diagnosis, early diagnosis, disease stage, neurodegenerative diseases
- MeSH terms
- Aged, Basal Ganglia Diseases, Female, Humans, Male, Middle Aged, Supranuclear Palsy, Progressive, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
